» Articles » PMID: 24396440

Diagnosis of Bladder Cancer from the Voided Urine Specimens Using Multi-target Fluorescence Hybridization

Overview
Journal Oncol Lett
Specialty Oncology
Date 2014 Jan 8
PMID 24396440
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to evaluate the diagnostic value of chromosomal analysis by fluorescence hybridization (FISH) for bladder cancer in light of the histological diagnosis. Several valuable observations using FISH technologies in voided urine cells were also reported. The multi-target FISH-containing probes for the centromeres of chromosomes 3, 7 and 17 and the 9p21 locus were applied to cytospin specimens prepared from voided urine. Urine samples from 53 bladder cancer patients and 30 patients with benign alterations were used for this study. The histological observations of surgical resection specimens showed that the specificity and sensitivity for the technique were 100.0 and 88.0%, respectively. Statistical analyses showed that there was no significant correlation between FISH-positive rate and the tumor stage/grade (P<0.05). However, the proportion of tumor cells with genetic abnormalities positively correlated with the tumor stage (P<0.01). Furthermore, the number of abnormal cells in muscle-invasive pT2 was significantly higher than that in non-muscle-invasive pTa, pT1 (P<0.01). Of 50 patients with bladder cancer, polysomies of chromosomes 3, 7 and 17 were detected in 84.0, 48.0 and 78.0% of cases, respectively, and loss of the 9p21 gene was detected in 80.0% of cases. In addition, the detailed results from different urine specimens showed that FISH assay was required. FISH assay for chromosomes 3, 7 and 17 and 9p21 has a high specificity and sensitivity in the detection of bladder cancer and may reduce the necessity for cytoscopy treatment.

Citing Articles

Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer.

Gorbokon N, Wossner N, Ahlburg V, Plage H, Hofbauer S, Furlano K J Pathol Clin Res. 2024; 11(1):e70012.

PMID: 39668577 PMC: 11638363. DOI: 10.1002/2056-4538.70012.


Association between chromosomal aberration of exfoliated bladder cells in the urine and oxidative stress in patients with bladder transitional cell carcinoma.

Wang D, Feng J, Yuan G, Yang Y, Liu Y, Yang Y Oncol Lett. 2017; 14(1):137-144.

PMID: 28693145 PMC: 5494805. DOI: 10.3892/ol.2017.6128.

References
1.
Sauter G, Simon R, Bubendorf L, Mihatsch M . [Molecular genetics of urinary bladder cancer progression]. Verh Dtsch Ges Pathol. 2003; 86:49-56. View

2.
Laudadio J, Keane T, Reeves H, Savage S, Hoda R, Lage J . Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005; 96(9):1280-5. DOI: 10.1111/j.1464-410X.2005.05826.x. View

3.
Panani A, Kozirakis D, Anastasiou J, Babanaraki A, Malovrouvas D, Roussos C . Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening?. Anticancer Res. 2006; 26(2A):1161-5. View

4.
Fritsche H, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W . Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 2010; 134(4):597-603. DOI: 10.1309/AJCPKKWBDSAOZ4RW. View

5.
Hermann G, Mogensen K, Toft B, Glenthoj A, Pedersen H . Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 2011; 46(1):31-6. DOI: 10.3109/00365599.2011.637954. View